Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study.
convenience
direct oral anticoagulants
quality of life
treatment satisfaction
warfarin
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
02
2019
accepted:
27
03
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
17
10
2019
Statut:
epublish
Résumé
Patient quality of life (QOL) while on long-term oral anticoagulant therapy has been receiving greater attention in recent years due to the increase in life expectancy brought about by advances in medical care. This study aimed to compare the QOL, treatment satisfaction, hospitalization and bleeding rate in patients on long-term warfarin versus direct oral anticoagulants (DOAC). This was a cross-sectional study of patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) on long-term anticoagulant therapy attending the cardiology clinic and anticoagulation clinic of the University Malaya Medical Centre from July 1, 2016, to June 30, 2018. Patient QOL was assessed by using the Short Form 12 Health Survey (SF12), while treatment satisfaction was assessed by using the Perception of Anticoagulation Treatment Questionnaire 2 (PACT-Q2). A total of 208 patients were recruited; 52.4% received warfarin and 47.6% received DOAC. There was no significant difference in QOL between warfarin and DOAC based on SF12 (physical QOL, Compared to warfarin, treatment of NVAF and VTE with DOAC showed comparable QOL, higher treatment satisfaction, lesser hospitalization, and a non-significant trend toward fewer bleeding episodes.
Identifiants
pubmed: 31616136
doi: 10.2147/PPA.S204246
pii: 204246
pmc: PMC6698611
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1363-1373Informations de copyright
© 2019 Ng et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Chest. 2018 Nov;154(5):1121-1201
pubmed: 30144419
Br J Haematol. 2013 Oct;163(2):160-7
pubmed: 23937286
Hum Genet. 2007 Mar;121(1):23-34
pubmed: 17048007
Arch Intern Med. 2005 May 23;165(10):1095-106
pubmed: 15911722
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Am J Manag Care. 1997 Apr;3(4):579-94
pubmed: 10169526
Health Qual Life Outcomes. 2009 Apr 07;7:30
pubmed: 19348685
Health Qual Life Outcomes. 2009 Feb 06;7:9
pubmed: 19196486
Br J Haematol. 2017 Sep;178(6):838-851
pubmed: 28573648
J Clin Epidemiol. 2010 Sep;63(9):1020-9
pubmed: 20189764
Patient Prefer Adherence. 2018 Jan 04;12:79-87
pubmed: 29379275
Int J Med Sci. 2014 May 01;11(7):680-4
pubmed: 24843316
Thromb Res. 2015 Feb;135(2):281-8
pubmed: 25483215
Int J Cardiol. 2013 Oct 3;168(3):2540-7
pubmed: 23664436
Arch Intern Med. 1991 Oct;151(10):1944-9
pubmed: 1929681
Thromb Res. 2014 Apr;133(4):550-4
pubmed: 24448058
Value Health. 2014 Nov;17(7):A496-7
pubmed: 27201490
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Thromb Haemost. 1993 Mar 1;69(3):236-9
pubmed: 8470047
Med Care Res Rev. 1996 Mar;53(1):3-27
pubmed: 10156434
Anatol J Cardiol. 2015 Jul 14;16(7):474-481
pubmed: 26680544
Health Qual Life Outcomes. 2011 Oct 25;9:91
pubmed: 22027368
J Comp Eff Res. 2017 Jun;6(4):303-312
pubmed: 28353372
Patient Prefer Adherence. 2017 Sep 25;11:1625-1634
pubmed: 29026288
Int J Clin Pharmacol Ther. 2013 Jul;51(7):549-61
pubmed: 23458226
TH Open. 2018 Apr 11;2(2):e139-e146
pubmed: 31249937
Circulation. 2008 Nov 11;118(20):2029-37
pubmed: 18955670
J Thromb Haemost. 2015 Nov;13(11):2119-26
pubmed: 26764429
J Thromb Haemost. 2004 Apr;2(4):584-91
pubmed: 15102012
Curr Med Res Opin. 2005 Jul;21(7):1085-90
pubmed: 16004677
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Thromb Res. 2015 Jul;136(1):69-75
pubmed: 25956287